EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease

Ehiremen M Iyoha, Sarah M Jenkins, Ruifeng Guo, Garret Choby

Otolaryngology–Head and Neck Surgery · 2024

DOI: 10.1002/ohn.850 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2024. Verfasst von Ehiremen M Iyoha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Melanoma, Neoplasm Recurrence, Local, Immunotherapy, Nasal Mucosa. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sinonasal mucosal melanoma (SNMM) is a rare malignancy with poor prognosis and high recurrence rate. In those with recurrence, survival is dismal. Immunotherapy is an emerging area of investigation; however, there is a scarcity of data on immunotherapy outcomes in SNMM patients with recurrence. We report outcomes of immunotherapy in recurrent SNMM patients with distant versus nondistant recurrence. Fifty‐four patients with recurrent SNMM were identified, and 31 (57.4%) had distant recurrence. One‐year overall survival (OS) following recurrence was 47.5% (95% confidence interval [CI]: 34.0%‐60.9%), with a median survival of 2.8 years (95% CI: 2.0‐5.3). In those with distant recurrence, receipt of immunotherapy was associated with better OS compared to those without immunotherapy (hazard ratio [HR] = 0.29 [95% CI: 0.12‐0.68], P = .004). While patients with nondistant recurrence (n = 23), who received immunotherapy (n = 6) had worse OS compared to those who did not receive immunotherapy (HR = 4.76 [95% CI: 1.36, 15.89], P = .02). Level of Evidence Level IV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNeoplasm Recurrence, LocalImmunotherapyNasal MucosaParanasal Sinus NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeAdultSurvival RateAged, 80 and over

Stichwörter der Autor:innen

immunotherapyrecurrencesinonasal mucosal melanoma

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Zitieren

APA

Iyoha, E. M., Jenkins, S. M., Guo, R., & Choby, G. (2024). Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.850

Vancouver

Iyoha EM, Jenkins SM, Guo R, Choby G. Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.850

BibTeX
@article{Iyoha2024,
  author = {Iyoha, Ehiremen M and Jenkins, Sarah M and Guo, Ruifeng and Choby, Garret},
  title = {Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2024},
  doi = {10.1002/ohn.850}
}
Kostenlos starten →